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We reported a novel interaction between Beclin 1, a key regulator of autophagy, and survivin, a
member of the inhibitor of apoptosis protein family. We found that knock-down of Beclin 1
down-regulated survivin protein, and the turnover rate of survivin was increased when Beclin 1
expression was silenced. Knock-down of Beclin 1 sensitized glioma cells to TRAIL-induced apoptosis,
and introduction of survivin antagonized the sensitizing effect, suggesting that down-regulation of
survivin mediates the enhanced sensitivity to TRAIL-induced apoptosis. These results demonstrate a
novel interaction between Beclin 1 and survivin, and may provide a potential mechanism underly-
ing the cross-talk between autophagy and apoptosis.
Structured summary:
MINT-7969366: Beclin-1 (uniprotkb:Q14457) physically interacts (MI:0915) with survivin (uni-
protkb:O15392) by anti tag coimmunoprecipitation (MI:0007)
MINT-7968986, MINT-7969161: survivin (uniprotkb:O15392) physically interacts (MI:0915) with Beclin-1
(uniprotkb:Q14457) by anti bait coimmunoprecipitation (MI:0006)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Inhibitor of apoptosis proteins (IAPs) are known to play a key
role in apoptosis suppression, signal transduction, and cell prolifer-
ation in tumor cells [1]. Survivin, a structurally unique IAP, is the
smallest member of the IAP family in mammalian cells and is able
to antagonize apoptosis, promote tumor-associated angiogenesis
and act as a resistance determinant to various anticancer therapies
[2]. Survivin has also been reported to play a pivotal role in onco-
genesis and progression of malignant brain tumors [3]. Beclin 1,
the mammalian homologue of the yeast Atg6, is a key autoph-
agy-promoting protein that regulates the formation of autophago-
some. The function of Beclin 1 has been shown to contribute to
inhibition of tumorigenesis in human malignancies [4]. Notably,chemical Societies. Published by E
TRAIL, tumor necrosis factor-
e
e of Medicine, Department of
A 17033, United States. Fax:
study.it has been demonstrated recently that Beclin 1 can interact with
the anti-apoptotic protein Bcl-2 and this interaction impacts on
the activity of both apoptosis and autophagy [5]. Beclin 1 may
exert its pro-survival effects via interactions with either Bcl-2 or
Bcl-xL, and Bcl-2 can function as an anti-autophagic protein
through its inhibitory interaction with Beclin 1 [6,7]. These studies
indicate that the apoptotic and autophagic machineries might be
functionally related and cross-talked. In the current study, we ob-
served a novel interaction between Beclin 1 and survivin. We dem-
onstrated that Beclin 1 was able to physically bind to survivin, and
that knock-down of Beclin 1 resulted in a down-regulation of sur-
vivin protein. Furthermore, we showed that decrease of Beclin 1
sensitized the human glioma cells, T98G and LN229, to TRAIL-
induced apoptosis, and this sensitizing effect appeared to be a con-
sequence of the down-regulation of survivin caused by depletion of
Beclin 1. Our ﬁnding of the interaction between survivin and Beclin
1 may aid in the elucidation of the mechanisms underlying the
cross-talk between autophagy and apoptosis, and provide evidence
for develop novel strategies to sensitizing tumor cells to apoptosis
inducers such as tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) via suppressing Beclin 1 expression.lsevier B.V. All rights reserved.
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2.1. Cell culture
The human glioblastoma cell lines, T98G and LN229, and the
human kidney epithelial cell line 293T, were purchased from
American Type Culture Collection. The human glioblastoma cell
line U251 was a gift from Dr. Jong Yun (Penn State College of
Medicine). T98G cells were cultured in Ham’s F-10/DMEM 10:1;
LN229, U251, and 293T cells were cultured in DMEM. All cell
culture media were supplemented with 10% fetal bovine serum,
100 units/ml penicillin, and 100 lg/ml streptomycin. Cells were
maintained at 37 C in a humidiﬁed atmosphere containing 5%
CO2/95% air.
2.2. Reagents and antibodies
MG132 and cyclohexamide were obtained from Calbiochem.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was purchased from Sigma. Recombinant human TRAIL
was obtained from PeproTech. All cell culture media and supple-
ments were purchased from Invitrogen. The following antibodies
were used in this study: rabbit anti-survivin, anti-Beclin 1, anti-
cleaved PARP, anti-cleaved caspase 7, and anti-cleaved caspase
9 (Cell Signaling); mouse anti-ﬂag and anti-tubulin (Sigma);
mouse anti-LC3 (Nanotools); mouse anti-caspase 8 (Alexis
Biochemicals).
2.3. siRNA transfection
Cells were cultured in six-well plates at 30–40% conﬂuence on
the day of transfection. Control or Beclin 1 (Dharmacon, J-
010552-05) siRNA at ﬁnal concentration of 17 nM was mixed with
2.5 ll RNAi MAX (Invitrogen) for each well, according to the man-
ufacturer’s protocol. After 72 h of transfection, cells were collected
for further experiments.Fig. 1. Knock-down of Beclin 1 down-regulates survivin in human glioma cells. Human g
(mock), a control, non-targeting RNA, or a Beclin 1 siRNA. After 72 h of transfection, cells
indicated. Tubulin was used as a loading control. (D) Quantiﬁcation of panels A–C. Resu2.4. Western blotting
Cells were lysed in Complete-M buffer (Roche) supplemented
with protease inhibitor cocktail (Roche) at room temperature for
5 min followed by centrifugation at 14 000g for 10 min. Concen-
trations of protein of the cell lysates were measured by the Bio-Rad
DC assay (Bio-Rad), according to the manufacturer’s instruction.
Protein (20–40 lg) were resolved on SDS–PAGE and transferred
to PVDF membrane (Bio-Rad). The blots were incubated with indi-
cated antibodies in 3% BSA/TBST at 4 C for overnight followed by
incubation with secondary antibodies at room temperature for
1 h. The signal was detected by ECL (Thermo Scientiﬁc).
2.5. Real-time reverse transcription-PCR
Total RNAs were isolated from the treated cells using the Tri-
Pure isolation reagent (Roche) according to the manufacturer’s
instruction. The concentrations of total RNAs were measured using
a NanoDrop (Thermo Scientiﬁc). First-strand cDNA was synthe-
sized using Omniscript reverse transcription kit (Qiagen) with ran-
dom primers, according to the manufacturer’s instruction. Real-
time PCR was performed on a Stratagene Mx3005P using Brilliant
II SYBR Green QPCR master mix (Stratagene) and following primer
sets: survivin, 50-CCCGATGACAACCCGATA-30 (forward) and 50-
CATCTGCTTCTTGACAGTGAG-30 (reverse); glyceraldehydes-3-
phosphate dehydrogenase, 50-TGCCTCTTTAGTTGTCATGCAG-30
(forward) and 50-CCCGTTCAGCTCAGGGATGA-30 (reverse). After
40 cycles, data were collected and analyzed by MxPro software
(Stratagene).
2.6. Pulse – chase experiments
Cells were transfected with a control siRNA or Beclin 1 siRNA for
72 h. Following the transfection, the cells were treated with cyclo-
hexamide (10 lg/ml) for 16 h, followed by release into cyclohexa-
mide-free media for the indicated times. Cell extracts werelioma cell lines LN229 (A), T98G (B), and U251 (C) were transfected with null siRNA
were collected and subjected to Western blot analysis with the speciﬁc antibodies as
lts shown are the representative of three identical experiments.
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using anti-survivin, anti-Beclin 1 or and anti-b-actin antibodies.
2.7. Immunoprecipitation
293T cells grown on 10-cm tissue culture dishes were transfec-
ted with a ﬂag-beclin and survivin expression vector using Lipofac-
tamine 2000 (Invitrogen), according to the manufacturer’s
protocol. After 24 h of transfection, cells were lysed in 1% Triton
X-100, 50 mM Tris pH 7.5, 300 mM NaCl, and 5 mM EDTA with
protease inhibitor cocktail (Roche), and centrifuged at 14 000g
for 10 min. Supernatant was collected and pre-cleared with Protein
A/G agarose beads (Santa Cruz) at 4 C for 30 min. Control IgG (rab-
bit) and speciﬁc antibodies were added to lysates and incubated at
4 C for overnight. The mixture was further incubated with 30 ll of
Protein A/G agarose beads at 4 C for 2 h. Beads were washed threeFig. 2. Survivin transcription is not affected by knock-down of Beclin 1. LN229,
U251, and T98G cells were transfected with a control or Beclin 1 siRNA for 72 h;
total RNAs from the treated cells were isolated and subjected to quantitative real-
time RT-PCR, as described in Section 2. GAPDH was used as an internal control, and
survivin mRNA was normalized to GAPDH. Results shown are the mean ± S.D. of
triplicate determinations from one of three identical experiments.
Fig. 3. Effect of silencing Beclin 1 expression on degradation rate of survivin. (A) LN229 ce
for survivin in the presence of 50 lg/ml CHX at indicated time points, as described in Se
LN229 cells were transfected with a control or Beclin 1 siRNA for 72 h, followed by the tre
of 50 lg/ml CHX at indicated time points. (D) Quantiﬁcation of panel C. Results showntimes with 0.1% Triton X-100, 50 mM Tris pH 7.5, 300 mM NaCl,
and 5 mM EDTA. Following a ﬁnal wash with PBS, the samples
were mixed with 1 SDS–PAGE loading buffer, heated at 70 C
for 10 min, and subjected to SDS–PAGE and Western blot analysis.
2.8. Caspase Activity Assay
For assaying the pan – caspase activity, the Guava multi-caspase
detection protocol was followed. Brieﬂy, 10 ll of caspase detection
reagent was added to 1  104 cells (in 100 ll) and the cells were
incubated for 1 h at 37 C with 5% CO2. Following the incubation,
the cells were washed twice with washing buffer and then re-sus-
pended in 200 ll of the caspase 7-AAD working solution. The sam-
ples were further incubated for 10 min at room temperature,
followed by analysis of caspase activity on a Guava ﬂow cytometry.
2.9. Cell viability assay
Cell viability was determined using MTT assay. Brieﬂy, cells
were seeded in 96-well tissue culture plates and subjected to dif-
ferent treatments. At the end of treatments, cells were incubated
with 20 ll of 5 mg/ml MTT reagent. After 4 h of incubation at
37 C in a humidiﬁed atmosphere containing 5% CO2, formazan
crystals were dissolved in 200 ll DMSO. Absorbance at 570 nm
was measured using a Bio-Tek plate reader.
3. Results and discussion
In study of the relationship between regulators of autopahgy
and apoptosis, we found in human glioma cell lines LN229, T98G,
and U251 that when expression of Beclin 1 was silenced using siR-
NA, the expression of survivin protein was also decreased (60%,
40%, and 70%, respectively), as examined by Western blot
(Fig. 1A–C). Since transcriptional repression of survivin by tumor
suppressors such PTEN and p53 through different mechanisms
has been previously reported [8,9], we next asked whether or not
the down-regulation of survivin by knock-down of Beclin 1
resulted from transcriptional repression of this anti-apoptoticlls were transfected with a control siRNA or Beclin 1 siRNA for 72 h, and then chased
ction 2. Survivin was detected using Western blot. (B) Quantiﬁcation of panel A. (C)
atment with 10 lg/ml of MG132 for 1 h. Survivin protein was chased in the presence
are the representative of three identical experiments.
Fig. 4. Detection of association of survivin with Beclin 1. (A) 293T cells were co-
transfected with a ﬂag-Beclin 1 and a survivin expression vector in the presence or
absence of a Beclin 1 – targeted siRNA. Forty-eight hours after transfection, cells
were collected for immunoprecipitation with either ﬂag (right panel) or survivin
(left panel) antibodies. IgGs were used as a negative control. Immunoprecipitates
were subjected to Western blot analysis using an anti-ﬂag or anti-survivin
antibody. (B) Cells co-transfected with a ﬂag-Beclin 1 and a survivin expression
vector were treated with or without HBSS for 4 h, followed by immunoprecipitation
with either a survivin (left panel) or a ﬂag (right panel) antibody and immuno-
blotting with a ﬂag or survivin antibody. Results shown are the representative of
three similar experiments.
3522 T.-K. Niu et al. / FEBS Letters 584 (2010) 3519–3524protein. We performed the real-time RT-PCR analysis of survivin
mRNA in cells transfected with a beclin 1-targeted siRNA or a
non-targeted siRNA. We found that the mRNA levels of survivin
were not decreased in glioma cells with silencing of Beclin 1, as
compared with that in non-targeting siRNA-transfected cells
(Fig. 2), indicating that the down-regulation of survivin induced
by suppression of Beclin 1 expression was transcription-
independent.
Survivin is a short-lived protein that is degraded by the ubiqui-
tin-proteasome pathway [10]. Therefore, we wanted to know
whether knock-down of Beclin 1 reduced survivin through facili-
tating the degradation of survivin by the ubiquitin-proteasome
system. To compare the turnover rate of survivin in cells with or
without silencing of Beclin 1 expression, we pulse-chased the sur-
vivin protein in LN229 cells transfected with a beclin 1-targeted
siRNA or a non-targeting siRNA in the presence of cycloheximide
(CHX), an inhibitor of protein synthesis. We observed a slight in-
crease in the turnover rate of survivin in the cells whose expressionFig. 5. Knock-down of Beclin 1 sensitizes human glioma cells to TRAIL-induced apoptos
TRAIL following the transfection with a control or Beclin 1 siRNA for 72 h. The treated cel
as indicated. Tubulin was used as a loading control. Results shown are the representativof Beclin 1 was silenced, as compared with that in control cells (t1/2
of survivin protein was 23 min and 30 min, respectively) (Fig. 3A
and B). Treatment with the proteasome inhibitor, MG132, caused
an accumulation of survivin in the cells either transfected with a
beclin 1-targeted siRNA or a non-targeting siRNA (Fig. 3C and D).
These results presented an evidence for a role of Beclin 1 in regu-
lating the cellular content of survivin. Nevertheless, whether or not
the interaction between survivin and Beclin 1 affects the turnover
of Beclin 1 remains to be explored. Additionally, in the presence of
MG132, survivin level in the cells transfected with a Beclin 1 siRNA
could not be fully rescued to the control level (Fig. 3C), suggesting
that the effects of Beclin 1 on the turnover of survivin could be
mediated through other mechanism in addition to the proteasomal
pathway.
To explore how Beclin 1 regulates the content of survivin, we
determined whether Beclin 1 and survivin physically interacted
using a co-immunoprecipitation approach. In these experiments,
293T cells with or without silencing of Beclin 1 expression were
transfected with a Flag-Beclin 1 and a survivin expression vector,
and cell lysates from the transfected cells were then subjected to
immunoprecipitation with an antibody to survivin and immuno-
blotting with an antidody to Beclin 1, or subjected to immunopre-
cipitation with an antibody to Flag and immunoblotting with an
antibody to survivin. Fig. 4A demonstrated that Beclin 1 was co-
immunoprecipitated with the anti-survivin antibodies, and vice
versa. However, Beclin 1 was not detected in the survivin immuno-
precipitates when Beclin 1 was silenced (Fig. 4A, left panel). Fur-
thermore, the interaction between Beclin 1 and survivin was also
identiﬁed in the cells subjected to nutrient starvation (cultured
in HBSS) (Fig. 4B). These results suggest that there is indeed a phys-
ical association between Beclin 1 and survivin, and this interaction
might account, at least in part, for the effect of Beclin 1 on survivin
protein levels as shown in Fig. 1. However, we did not observed
changes in the physical association between survivin and beclin
1 following nutrient starvation (Fig. 4B), probably due to that, this
level of interaction is adequate for inducing autophagy and for
modulating cell survival, or there exist other factors (e.g., Bcl-2,
Bcl-xL, etc.) controlling the interaction between these two pro-
teins. In addition, the exact binding sites on both of the proteins,
and whether this interaction is spatially – restricted or tissue –
selective, are currently unknown, and remain to be investigated.
To begin to understand the functional signiﬁcance of the inter-
action between Beclin 1 and survivin, we tested the effect of
knocking down Beclin 1 on sensitivity of glioma cells to TRAIL,is. U251 (A) and LN229 (B) cells were treated with the indicated concentrations of
ls were collected and subjected to Western blot analysis with the speciﬁc antibodies
e of three identical experiments.
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Fig. 6. Knock-down of Beclin 1 enhances TRAIL-induced caspase activities in human glioma cells. T98G (A), LN229 (B), and U251 (C) cells transfected with a control or Beclin 1
siRNA were treated with 200 ng/ml TRAIL for 24 h. Pan-caspase activities were measured using ﬂow cytometry. Each point represents mean ± S.D. of three independent
assays; *P < 0.05, **P < 0.01, t-test.
Fig. 7. Introduction of survivin rescues the TRAIL-induced cell death in glioma cells with silencing of Beclin 1 expression. T98G cells were co-transfected with a non-targeting
siRNA and a control vector, or a Beclin 1 siRNAs and a control vector, or a Beclin 1 siRNA and a survivin expression vector for 48 h. (A) Cells were collected and subjected to
Western blot with survivin antibody. Tubulin was used as a loading control. (B) Cells were treated with various concentrations of TRAIL and cell viability was determined
using MTT assay, as described in Section 2. Results shown are the mean ± S.D. of quadruplicate determinations from one of three identical experiments. *P < 0.05, t-test.
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of survivin renders glioma cells sensitivity to TRAIL-induced apop-
tosis in glioma cells and overexpression of survivin attenuated
apoptosis induced by TRAIL [11]. As shown in Fig. 5A, while
knock-down of Beclin 1 reduced survivin levels, it also lead to an
increase in apoptosis, as indicated by a dose-dependent increase
in the levels of cleaved PARP, cleaved caspase 7, cleaved caspase
8, and cleaved caspase 9 in glioma cells treated with TRAIL. En-
hanced sensitivity to TRAIL-induced apoptosis was also observed
in LN229 cells with silencing of Beclin 1 expression (Fig. 5B). To
verify the effect of knock-down of Beclin 1 on TRAIL-induced apop-tosis, we measured the pan – caspase activity using ﬂow cytome-
try. As shown in Fig. 6, inhibition of Beclin 1 increased the
caspase activities in T98G, LN229, and U251 cells treated with
TRAIL. To corroborate that the sensitizing effect of suppressing Be-
clin 1 expression on TRAIL-induced apoptosis was mediated by
down-regulation of survivin, we co-transfected glioma cells with
a Beclin 1 siRNA and a survivin expression vector, followed by
the treatment with TRAIL for 24 h. An empty vector was used as
a control. As shown in Fig. 7, transfection with the survivin expres-
sion plasmid signiﬁcantly lessened the TRAIL-induced cytotoxicity
in tumor cells with silencing of Beclin 1, as compared with the
3524 T.-K. Niu et al. / FEBS Letters 584 (2010) 3519–3524transfection with a control plasmid (Fig. 7), suggesting that the
reduction of survivin indeed contributes to the enhanced sensitiv-
ity to the TRAIL-induced apoptosis in cells with depletion of Beclin
1. Nevertheless, at present the indirect effect of interaction be-
tween Beclin 1 and survivin on cell viability can not be excluded.
Previous studies have demonstrated the interaction between
Beclin 1 and anti-apoptotic Bcl-2 family proteins [5–7]. In this
study, we identiﬁed for the ﬁrst time the interaction between Be-
clin 1 and survivin, a member of IAPs. As Beclin 1 is a key regulator
of autophagy, the interaction between Beclin 1 and survivin might
reﬂect a functional relationship between autophagy and apoptosis,
two major cell death and survival mechanisms that impact a vari-
ety of physiologic or patho-physiologic processes.
Evasion of apoptosis is a hallmark of most malignant cells
and contributes to insensitivity to various current cancer thera-
pies [12]. Apoptosis resistance can be induced by a number of
mechanisms, including aberrant expression of IAPs [13]. High
expressions of IAPs have been observed in many human cancers
[14], and are thus considered promising targets for cancer treat-
ment. In this study, we have also demonstrated that interaction
between Beclin 1 and survivin affects the sensitivity of human
glioma cells to TRAIL-induced apoptosis. TRAIL is known to in-
duce apoptosis in cancer cells with no or minimal toxicity on
normal cells. However, glioma cells are often found to be resis-
tant to TRAIL therapy. Combinations of TRAIL with other treat-
ments such as Smac agonist and rapamycin have been shown
to sensitize glioma cells to TRAIL-induced apoptosis [15,16]. Also,
inhibition of autophagy in tumor cells allows for the induction of
signiﬁcant apoptosis in response to TRAIL [17]. The results of
this study present a possible new mechanism regulating the
cross-talk between apoptosis and autophagy, and may help de-
velop new strategies to sensitize tumor cells to apoptosis induc-
ers such as TRAIL therapy. Taken together, our study provides
evidence for a potentially important interaction between Beclin
1 and survivin and the therapeutic implication of this interaction
in human tumor cells.
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